Medical Oncologist
ALK-positive lung cancer
Alectinib Outcomes: — An Honest Look at the Numbers
When a doctor prescribes alectinib, the first question most families ask is how well it works. The honest answer involves understanding what clinical trial numbers actually mean — and why the same median figure can describe very different individual experiences.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- A median is a midpoint, not a promise — Half of patients in trials do better than the median, and half do not reach it. Knowing this changes how you read any figure.
- Alectinib is established in guidelines — NCCN, ESMO and ASCO all list alectinib as a preferred first-line treatment for ALK-positive non-small cell lung cancer.
- Responses vary widely — Some people respond for far longer than trial medians suggest. Others progress earlier. Your oncologist can discuss what factors are relevant to you.
- Numbers from trials describe groups — They are the best information available, but they are not individual predictions. Your situation, fitness and tumour biology all affect the picture.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Alectinib is one of the most effective targeted therapies for ALK-positive non-small cell lung cancer. Outcomes data from the ALEX phase 3 trial, cited in NCCN, ESMO and ASCO guidelines, shows a median progression-free survival considerably longer than earlier ALK inhibitors. A median is a group midpoint — half of patients did better than it, half did not.
What do these terms mean?
- Progression-free survival (PFS)
- How long treatment keeps the cancer from growing or spreading. It is measured from when treatment starts to when the cancer progresses, or the person dies.
- Overall survival (OS)
- How long a person lives after starting treatment. This is the number most families mean when they ask about survival.
- Median
- The midpoint of a group of results. If a trial reports a median PFS of two years, half the participants had progression-free survival longer than two years, and half had shorter. It is not a ceiling, and it is not a prediction for any individual person.
- Objective response rate
- The proportion of patients whose tumour shrank by a measurable amount during treatment. A response is not the same as long-term disease control, and it is not the same as cure.
- ALK-positive NSCLC
- A lung cancer driven by a change in the ALK gene. Alectinib is designed specifically for this subtype and is not used for cancers that do not carry this change.
What does a median survival figure actually mean for you?
A median is a midpoint. It tells you what the middle experience in a trial looked like — nothing more and nothing less.
If you line up every trial participant by how long their treatment worked, the median is the result of the person in the exact middle. Half the people in that line did better. Half did not do as well.
This matters because survival data describes a group of hundreds of people. You are one person with your own tumour biology, fitness and other health factors. The number tells you where alectinib sits relative to other options — not what your individual trajectory will be.
Range matters too. Trial results include a confidence interval alongside the median. The upper end of that range shows that a meaningful proportion of patients responded for considerably longer than the midpoint. Your oncologist can explain what the published range looked like and what it means for your specific situation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
Is alectinib considered effective for ALK-positive lung cancer?
Yes. NCCN, ESMO and ASCO all list alectinib as a preferred first-line treatment for ALK-positive non-small cell lung cancer, a designation based on evidence from the ALEX phase 3 trial and subsequent data.
The ALEX trial showed that alectinib produced meaningfully longer progression-free survival than crizotinib, the earlier standard of care. It also crosses into the central nervous system, which matters because ALK-positive lung cancer has a tendency to spread to the brain.
Response rates reported by ESMO and NCCN for alectinib are high for a targeted therapy. Most people on alectinib see their tumour shrink or stabilise, at least initially.
What the evidence cannot tell you is how long that response will last in your case. Some people remain on alectinib for several years without progression. Others progress earlier. Your oncologist, who knows your staging, your scans and your overall health, is better placed to guide that conversation than any published median.
Did you know?
Alectinib crosses the blood-brain barrier, which matters because ALK-positive lung cancer has a particular tendency to spread to the brain.
In the ALEX trial, alectinib significantly reduced central nervous system progression compared with crizotinib. For people living with this diagnosis, that is a meaningful practical difference — not just a trial endpoint.
Source: ALEX Trial results, cited in NCCN Guidelines for Non-Small Cell Lung Cancer and ESMO Clinical Practice Guidelines for Metastatic NSCLC
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What does the median progression-free survival figure mean for my prognosis?
A median is a group midpoint. In a trial, half the participants had progression-free survival longer than the median, and half had shorter. It does not set a ceiling on how long your treatment might work, and it is not a forecast for your individual case. Your oncologist can explain what the published range looked like, because the range — not just the midpoint — gives a more complete picture of what is possible.
Did alectinib perform better than crizotinib in trials?
Yes. The ALEX phase 3 trial compared alectinib directly with crizotinib, the previous standard treatment for ALK-positive lung cancer, and alectinib produced meaningfully longer progression-free survival. It also showed a benefit in delaying brain progression. NCCN, ESMO and ASCO all updated their guidelines in response and now list alectinib as a preferred first-line option based on that evidence.
Is there a real chance of a much longer response than the median?
Yes. In every trial, a proportion of patients do considerably better than the median — sometimes for several years longer. The median describes the middle of the group, not the best achievable outcome. How large that longer-responding group was in the ALEX trial, and what factors were associated with longer responses, is something your oncologist can walk you through in the context of your own staging and scans.
Is a response rate the same as a cure rate?
No, and this distinction matters. A response rate is the proportion of patients whose tumour shrank by a measurable amount during treatment. Shrinkage is important — it usually means the treatment is working — but it does not mean the cancer has gone. Alectinib aims to control the cancer for as long as possible. If your oncologist uses the word cure, ask them to clarify exactly what they mean in your specific situation.
What happens when alectinib eventually stops working?
Most people on alectinib eventually develop resistance and the cancer starts growing again. When that happens, the next step depends on what resistance mechanism is driving the progression. Other ALK inhibitors are options in many cases, and NCCN and ESMO guidance addresses second-line treatment specifically. Knowing that further steps exist does not make progression less difficult, but it is genuinely the case that further options are available for most people.
Can I trust survival statistics I find online?
Treat any number found outside of your oncologist's office with care. Published trial medians are real data, but they describe patients who may differ from you in age, stage and other health conditions. Numbers from older papers may predate current treatments. General lung cancer statistics mix all subtypes together, which is not relevant to an ALK-positive diagnosis. Ask your oncologist to explain what the published data shows for people whose situation is closest to yours.